ReviewNanophotonics (Berlin, Germany)2025
Application of metasurface in future displays.
Review in Nanophotonics (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Programmable Multidimensional Diffraction Engineering via an Optically Addressed Nested Fourier Metasurface.Nanophotonics (Berlin, Germany) · 2026Article
- Advances in Structural Colors-Mechanisms, Quantitative Evaluation, and Applications: A Review.Nanomaterials (Basel, Switzerland) · 2026Review
- Compound Meta-Optics for Advanced Optical Engineering.Sensors (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optical metasurfaces, as a booming research field, have provided new methods for modulating the amplitude, phase, and polarization of light through artificial birefringent structures or structural resonances. It has been used to design planar optical components such as ultra-thin lenses, ultra-wideband achromatic lenses, and orbital angular momentum (OAM) generators. However, existing surveys typically examine either metasurface fundamentals or a single display modality, leaving no comprehensive roadmap that connects meta-atom design to full-device performance, hereafter, the term meta-atom are denoted to be an individual sub-wavelength building block of a metasurface. Here we present the first cross-scale review that quantitatively bridgices phase-dispersion engineering at the nanostructure level with system-level figures-of-merit across three mainstream 3D display paradigms, computer-generated holography, light-field projection, and near-eye/retinal displays. By critically benchmarking more than 150 demonstrations published between 2019 and 2025, we extract practical lookup charts that guide practitioners from material choice and meta-atom geometry to field-of-view, depth acuity, efficiency, and form-factor targets. Thanks to metasurfaces' high integration density and functional diversity, its application in the light field display has attracted great interest. Metasurface can effectively improve the shortcomings of low spatial resolution, low diffraction efficiency, and narrow field of view common in traditional display components. In this paper, we first review the phase modulation method and structure resonance principle of metasurface. Then, we examine their application in the holographic display field and review the approaches for achieving structural-color printing. We summarize the 3D display methods of holographic display, light field display, and near-eye display and discuss how metasufaces enhance each modality. Finally, we distill emerging inflection points: AI assisted inverse design, dynamically tunable multifunctional platforms, and quantum or cascaded architectures into a looking forward commercialization roadmap that addresses the challenges still facing the 3D display industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.